Bispecific antibody does not induce T-cell death mediated by chimeric antigen receptor against disialoganglioside GD2

OncoImmunology

Volumn 6, Issue 6, 2017, Pages

  Hoseini, Sayed Shahabuddin ^a   Dobrenkov, Konstantin ^a   Pankov, Dmitry ^a   Xu, Xiaoliang L ^a   Cheung, Nai Kong V ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Bispecific antibody; chimeric antigen receptor; disialoganglioside; immunotherapy; T cell exhaustion

Indexed keywords

BICLONE 119; BISPECIFIC ANTIBODY; CD3 ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; GANGLIOSIDE GD2; HU3F8; HU3F8 CHIMERIC ANTIGEN RECEPTOR; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DEATH; CELL SURVIVAL; CHROMIUM RELEASE ASSAY; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXICITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; GENETIC TRANSDUCTION; MALE; MELANOMA; MOUSE; NONHUMAN; T CELL DEPLETION; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR REGRESSION; TUMOR VOLUME;

EID: 85020257142     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2017.1320625     Document Type: Article

References (30)

1. Hiraoka K, Miyamoto M, Cho Y, Suzuoki M, Oshikiri T, Nakakubo Y, Itoh T, Ohbuchi T, Kondo S, Katoh H. Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinoma. Br J Cancer 2006; 94(2):275-80; PMID:16421594; https://doi.org/10.1038/sj.bjc.6602934
2. Sommermeyer D, Hudecek M, Kosasih PL, Gogishvili T, Maloney DG, Turtle CJ, Riddell SR. Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo. Leukemia 2016; 30(2):492-500; PMID:26369987; https://doi.org/10.1038/leu.2015.247
3. Cheung NK, Saarinen UM, Neely JE, Landmeier B, Donovan D, Coccia PF. Monoclonal antibodies to a glycolipid antigen on human neuroblastoma cells. Cancer Res 1985; 45(6):2642-9; PMID:2580625
4. Dobrenkov K, et al. Oncotargets GD2 and GD3 are highly expressed in sarcomas of children, adolescents, and young adults. Pediatr Blood Cancer. 2016 Oct; 63(10):1780-5; PMID:27304202; https://doi.org/10.1002/pbc.26097
5. Modak S, Gerald W, Cheung NK. Disialoganglioside GD2 and a novel tumor antigen:potential targets for immunotherapy of desmoplastic small round cell tumor. Med Pediatr Oncol 2002; 39(6):547-51; PMID:12376975; https://doi.org/10.1002/mpo.10151
6. Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, Smith M, Anderson B, Villablanca JG, Matthay KK, et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 2010; 363(14):1324-34; PMID:20879881; https://doi.org/10.1056/NEJMoa0911123
7. Cheung NK, Cheung IY, Kushner BH, Ostrovnaya I, Chamberlain E, Kramer K, Modak S. Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission. J Clin Oncol 2012; 30(26):3264-70; PMID:22869886; https://doi.org/10.1200/JCO.2011.41.3807
8. Cheung NK, Dyer MA. Neuroblastoma:developmental biology, cancer genomics and immunotherapy. Nat Rev Cancer 2013; 13(6):397-411; PMID:23702928; https://doi.org/10.1038/nrc3526
9. Pule MA, Savoldo B, Myers GD, Rossig C, Russell HV, Dotti G, Huls MH, Liu E, Gee AP, Mei Z, et al. Virus-specific T cells engineered to coexpress tumor-specific receptors:persistence and antitumor activity in individuals with neuroblastoma. Nat Med 2008; 14(11):1264-70; PMID:18978797; https://doi.org/10.1038/nm.1882
10. Louis CU, Savoldo B, Dotti G, Pule M, Yvon E, Myers GD, Rossig C, Russell HV, Diouf O, Liu E, et al. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood 2011; 118(23):6050-6; PMID:21984804; https://doi.org/10.1182/blood-2011-05-354449
11. Hudecek M, Sommermeyer D, Kosasih PL, Silva-Benedict A, Liu L, Rader C, Jensen MC, Riddell SR. The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity. Cancer Immunol Res 2015; 3(2):125-35; PMID:25212991; https://doi.org/10.1158/2326-6066.CIR-14-0127
12. Hombach A, Hombach AA, Abken H. Adoptive immunotherapy with genetically engineered T cells:modification of the IgG1 Fc ‘spacer’ domain in the extracellular moiety of chimeric antigen receptors avoids ‘off-target’ activation and unintended initiation of an innate immune response. Gene Ther 2010; 17(10):1206-13; PMID:20555360; https://doi.org/10.1038/gt.2010.91
13. Long AH, Haso WM, Shern JF, Wanhainen KM, Murgai M, Ingaramo M, Smith JP, Walker AJ, Kohler ME, Venkateshwara VR, et al. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat Med 2015; 21(6):581-90; PMID:25939063; https://doi.org/10.1038/nm.3838
14. Sun J, Dotti G, Huye LE, Foster AE, Savoldo B, Gramatges MM, Spencer DM, Rooney CM. T cells expressing constitutively active Akt resist multiple tumor-associated inhibitory mechanisms. Mol Ther 2010; 18(11):2006-17; PMID:20842106; https://doi.org/10.1038/mt.2010.185
15. Gargett T, Yu W, Dotti G, Yvon ES, Christo SN, Hayball JD, Lewis ID, Brenner MK, Brown MP. GD2-specific CAR T Cells undergo potent activation and deletion following antigen encounter but can be protected from activation-induced cell death by PD-1 blockade. Mol Ther 2016; 24(6):1135-49; PMID:27019998; https://doi.org/10.1038/mt.2016.63
16. Cheung NK, Canete A, Cheung IY, Ye JN, Liu C. Disialoganglioside GD2 anti-idiotypic monoclonal antibodies. Int J Cancer 1993; 54(3):499-505; PMID:8509225; https://doi.org/10.1002/ijc.2910540324
17. Jiao P, Otto M, Geng Q, Li C, Li F, Butch ER, Snyder SE, Zhou H, Yan B. Enhancing both CT imaging and natural killer cell-mediated cancer cell killing by a GD2-targeting nanoconstruct. J Mater Chem B Mater Biol Med 2016; 4(3):513-20; PMID:27087966; https://doi.org/10.1039/C5TB02243F
18. Hu J, Huang X, Ling CC, Bundle DR, Cheung NK. Reducing epitope spread during affinity maturation of an anti-ganglioside GD2 antibody. J Immunol 2009; 183(9):5748-55; PMID:19812201; https://doi.org/10.4049/jimmunol.0901409
19. Zhao Q, Ahmed M, Guo HF, Cheung IY, Cheung NK. Alteration of electrostatic surface potential enhances affinity and tumor killing properties of anti-ganglioside GD2 monoclonal antibody hu3F8. J Biol Chem 2015; 290(21):13017-27; PMID:25851904; https://doi.org/10.1074/jbc.M115.650903
20. Utzschneider DT, Alfei F, Roelli P, Barras D, Chennupati V, Darbre S, Delorenzi M, Pinschewer DD, Zehn D. High antigen levels induce an exhausted phenotype in a chronic infection without impairing T cell expansion and survival. J Exp Med. 2016 Aug 22; 213(9):1819-34; PMID:27455951; https://doi.org/10.1084/jem.20150598
21. Tanaka M, Tashiro H, Omer B, Lapteva N, Ando J, Ngo M, Mehta B, Dotti G, Kinchington PR, Leen AM, et al. Vaccination targeting native receptors to enhance the function and proliferation of chimeric antigen receptor (CAR)-modified T cells. Clin Cancer Res 2017; PMID:28183713; https://doi.org/10.1158/1078-0432.CCR-16-2138
22. Cherkassky L, Morello A, Villena-Vargas J, Feng Y, Dimitrov DS, Jones DR, Sadelain M, Adusumilli PS. Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. J Clin Invest 2016; 126(8):3130-44; PMID:27454297; https://doi.org/10.1172/JCI83092
23. Zhang S, Zhang H, Zhao J. The role of CD4 T cell help for CD8 CTL activation. Biochem Biophys Res Commun 2009; 384(4):405-8; PMID:19410556; https://doi.org/10.1016/j.bbrc.2009.04.134
24. Quezada SA, Simpson TR, Peggs KS, Merghoub T, Vider J, Fan X, Blasberg R, Yagita H, Muranski P, Antony PA, et al. Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med 2010; 207(3):637-50; PMID:20156971; https://doi.org/10.1084/jem.20091918
25. Teachey DT, Rheingold SR, Maude SL, Zugmaier G, Barrett DM, Seif AE, Nichols KE, Suppa EK, Kalos M, Berg RA, et al. Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood 2013; 121(26):5154-7; PMID:23678006; https://doi.org/10.1182/blood-2013-02-485623
26. Imai C, Mihara K, Andreansky M, Nicholson IC, Pui CH, Geiger TL, Campana D. Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia 2004; 18(4):676-84; PMID:14961035; https://doi.org/10.1038/sj.leu.2403302
27. Cobrinik D, Francis RO, Abramson DH, Lee TC. Rb induces a proliferative arrest and curtails Brn-2 expression in retinoblastoma cells. Mol Cancer 2006; 5:72; PMID:17163992; https://doi.org/10.1186/1476-4598-5-72
28. Zufferey R, Nagy D, Mandel RJ, Naldini L, Trono D. Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat Biotechnol 1997; 15(9):871-5; PMID:9306402; https://doi.org/10.1038/nbt0997-871
29. Xu H, Cheng M, Guo H, Chen Y, Huse M, Cheung NK. Retargeting T cells to GD2 pentasaccharide on human tumors using Bispecific humanized antibody. Cancer Immunol Res 2015; 3(3):266-77; PMID:25542634; https://doi.org/10.1158/2326-6066.CIR-14-0230-T
30. Cheng M, Ahmed M, Xu H, Cheung NK. Structural design of disialoganglioside GD2 and CD3-bispecific antibodies to redirect T cells for tumor therapy. Int J Cancer 2015; 136(2):476-86; PMID:24895182; https://doi.org/10.1002/ijc.29007